December 1, 2017 Duchenne Regulatory Science Consortium Meeting on Disease Progression Modeling for Duchenne Muscular Dystrophy
The Duchenne Regulatory Science Consortium – A public-private partnership to facilitate sharing of clinical data for the development of regulatory tools to accelerate drug development (Abstract)
March 8, 2015 Critical Path Institute Launches New Consortium Dedicated To Duchenne Muscular Dystrophy August 3, 2015 Critical Path Institute Launches New Consortium Dedicated To Duchenne Muscular Dystrophy Tucson, Arizona – August
FDA: Guidance for Industry Duchenne Muscular Dystrophy Developing Drugs for Treatment Over the Spectrum of Disease
The TREAT-NMD Advisory Committee for Therapeutics (TACT): An Innovative de-Risking Model to Foster Orphan Drug Development
